sk-mel2

BTYNB (MDK6620) is an inhibitor of the oncofetal mRNA-binding protein IMP1 (IC50 = 5 μM for IMP1 binding to c-Myc mRNA). MDK6620 downregulates β-TrCP1 mRNA and reduces activation of nuclear transcriptional factors-kappa B (NF-κB). It disrupts this enhancer function by impairing IGF2 mRNA-binding protein 1 (IGF2BP1)-RNA association

SHR902275 is a selective, potent, orally active RAF inhibitor capable of targeting RAS mutant cancers. SHR902275 acts on cRAF (IC50: 1.6 nM), bRAFwt (IC50: 10 nM), bRAFV600E (IC50: 5.7 nM). SHR902275 has cell growth inhibitory effects and acts on H358 cells (GI50: 1.5 nM), A375 cells (GI50: 0.17 nM), Calu6 cells (GI50: 0.4 nM) and SK-MEL2 cells (GI50: 0.32 nM).